Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NX 5948

Next Previous
X
Search
Drug Profile

NX 5948

Alternative Names: NX-5948

Latest Information Update: 18 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nurix
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Preclinical Graft-versus-host disease; Rhabdomyosarcoma

Most Recent Events

  • 17 Jun 2024 Updated efficacy and adverse events data from a phase Ia/Ib in B-cell malignancies released by Nurix Therapeutics
  • 16 Jun 2024 Nurix Therapeutics plans a pivotal trial for B-cell malignancies in 2025
  • 14 May 2024 Efficacy data from a phase Ia/Ib trial in B-cell malignancies released by Nurix Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top